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A 49-year-old man was admitted to our hospital with a 1-month history of dysphagia. An upper endoscopy
revealed a lower esophageal submucosal tumor. Immunohistochemical staining of the biopsy specimen revealed
KIT positivity. Thus, the tumor was diagnosed as a gastrointestinal stromal tumor (GIST). After 6 months of imatinib
treatment, the tumor decreased from 92 mm× 55 mm × 80 mm to 65 mm × 35 mm × 55 mm in diameter, and
surgery was performed. The tumor was completely resected without rupture, by partial esophagogastric resection
through a thoracotomy incision, using an abdominal laparoscopic approach. Immunohistochemical staining
revealed that the tumor was negative for c-kit but positive for CD34. Genetic examination showed that the tumor
had a mutation in exon 11. The patient experienced minor leakage but recovered conservatively. Adjuvant imatinib
was initiated 64 days after surgery. We report this rare case to show the potential of preoperative imatinib
treatment in patients with large esophageal GISTs, to achieve complete resection without rupture.
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Gastrointestinal stromal tumors (GISTs) are mesenchymal
tumors of the gastrointestinal tract, commonly found in the
stomach (60% to 70%) and small intestine (20% to 30%)
[1,2]. Surgery is the first treatment for resectable GISTs,
which cures approximately 60% of patients [3]. However,
the prognosis of patients who relapse is poor. Imatinib mes-
ylate is now the standard drug for patients with unresect-
able or metastatic GISTs and was recently approved for use
as an adjuvant treatment [4,5]. Currently, there is no evi-
dence of an effective neoadjuvant therapy for GISTs, espe-
cially for very large primary GISTs, which have an
increased risk of a positive resection margin [6]. As esopha-
geal GISTs are very rare, accounting for <2% of all GISTs
[2,7], the available literature is limited. Moreover, the use of
imatinib therapy followed by surgery has been published
only for a few cases [8]. We report a large esophageal GIST* Correspondence: ktanabe2@hiroshima-u.ac.jp
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distribution, and reproduction in any mediumin a 49-year-old man who underwent surgery after neoadju-
vant chemotherapy.Case presentation
A 49-year-old man was admitted to our hospital with a 1-
month history of dysphagia. He did not have any history of
illness or any significant family history. Physical examin-
ation revealed no abnormalities. Standard laboratory test
results on serum and urine showed no significant findings.
Tumor markers such as carcinoembryonic antigen, carbo-
hydrate antigenic determinant 19-9 and squamous cell car-
cinoma antigen were also within the reference limits. An
upper endoscopy revealed a submucosal tumor with a nar-
rowed lumen in the lower esophagus (Figure 1A). After a
fine-needle aspiration biopsy, the tumor was diagnosed as a
GIST, characterized pathologically by H & E staining and
immunostaining (Figure 1B,C,D). A computed tomography
(CT) scan showed a mass, 92 mm× 55 mm× 80 mm in
diameter (Figure 2A), at the lower esophagus and the max-
imum standardized uptake value (SUV max) was 4.9 on a
positron emission tomography (PET)-CT scan (Figure 2B).
There was no apparent distant metastasis. The tumor was
classified as intermediate risk according to Fletcher’stral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Preoperative image and tumor biopsy images. (A) Endoscopic image taken before chemotherapy showing the tumor with a
smooth surface in the lower esophagus. Histopathologically, H & E staining showed that the spindle tumor cells had no mitotic activity, as shown
at × 200 (B). The tumor cells were positive for c-kit, as shown at × 200, (C) and CD34, as shown at × 200, (D) using immunohistochemistry.
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risk for rupture during resection because of the size and
localization of the lesion. Therefore the patient received
neoadjuvant imatinib (400 mg/day) treatment and was
followed-up for 2 months with CT scans to assess the
therapeutic effect. He was treated for 6 months with
chemotherapy and the tumor shrank by 25% (Figure 2C). A
PET-CT scan showed a reduction in SUV max to 1.2
(Figure 2D).Figure 2 CT and PET-CT images. (A) CT scan before chemotherapy. The
chemotherapy. SUV max was 4.9. (C) CT scan after chemotherapy. The tum
chemotherapy. SUV max was 1.2.The patient underwent surgery after the chemother-
apy. The surgical procedure was a partial esophagogas-
tric resection through a thoracotomy incision, using an
abdominal laparoscopic approach. A lymphadenectomy
was not performed. On gross examination, the resected
tumor was soft and had shrunk to 65 mm × 35 mm ×
45 mm in diameter (Figure 3A). The esophageal mucosa
appeared normal without ulcerations. Histological ana-
lysis showed that the tumor consisted of spindle cellstumor was 92 × 55 mm× 80 mm in diameter. (B) PET-CT scan before
or was 70 mm× 37 mm× 60 mm in diameter. (D) PET-CT scan after
Figure 3 Resected surgical specimen. (A) The resected tumor was approximately 65 mm× 35 × 55 mm in diameter. (B) Histopathologically,
H & E staining showed that the tumor cells had no necrosis and mitotic activity, as shown at × 200. The tumor cells were negative for c-kit, as
shown at × 200, (C) and positive for CD34, as shown at × 200, (D) using immunohistochemistry.
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cal staining revealed that the spindle cells were negative
for c-kit (Figure 3C) but positive for CD34 (Figure 3D).
Genetic examination showed that the tumor had an
exon 11 mutation.
The patient experienced aspiration pneumonia and
minor leakage after the operation, but recovered conserva-
tively from both conditions. He was discharged 52 days
after the surgery, and adjuvant chemotherapy (imatinib,
400 mg/day) was initiated at 64 days after the surgery.
There has been no recurrence for 12 months post-surgery.Discussion
Complete surgical resection is the standard treatment for
localized GISTs; however, 40% to 90% of curative resection
patients experience recurrence [10]. Esophageal GISTs are
rare, highly vascularized tumors. Large tumors specifically
have a tendency to rupture or have a risk of a positive mar-
gin despite a macroscopically complete resection. Tumor
rupture or the presence of a residual tumor is strongly asso-
ciated with recurrence and poor prognosis [11,12].
The biological potential of stomach or small intestinal
GISTs is related to their size and mitotic activity, which
may also be true of esophageal GISTs. The prognosis is
commonly stratified according to the Joensuu risk cri-
teria [3] and accurate risk stratification is important in
considering adjuvant imatinib therapy. It has been estab-
lished that 3 years of adjuvant imatinib is beneficial for
recurrence-free survival and overall survival for-high risk
GISTs [4].Although the benefit of imatinib for malignant or
high-risk GISTs is beyond doubt, the clinical outcome
of neoadjuvant treatment has not yet been estab-
lished. In our case, we were able to a perform
complete resection of the GIST owing to the de-
creased tumor size after the treatment with imatinib.
The tumor was diagnosed to be of intermediate risk
according to Fletcher’s classification [9]. We used
neoadjuvant imatinib (400 mg/day for 6 months) to
achieve complete resection without rupture. In our
case, there was no rupture during the operation and
a pathologically negative margin was obtained. The
appropriate duration of neoadjuvant therapy with
imatinib is controversial. Most of the positive re-
sponses to chemotherapy occur within 6 months of
administration and secondary mutations may occur
after 10 months of treatment, hence some reports
suggest 6 months of neoadjuvant chemotherapy for
GISTs [13,14]. In our case, sufficient shrinkage of the
tumor was attained after 6 months of treatment;
therefore, a minimal resection could be performed
during esophagectomy. The reason for the negative
c-kit and positive CD34 findings, despite the tumor
being positive for both markers preoperatively, is
unclear. These biomarker changes may be because
of the therapeutic effect of imatinib; however,
whether these findings are indicative of a pathological
complete response is uncertain. Tumors could show a
completely altered morphology and immunophenotype
after imatinib treatment; thus, pathologists should be
aware of this phenomenon [15]. There have been
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sponse was obtained with imatinib treatment even in
patients with metastatic GISTs [16].
In summary, we reported a case of a large esophageal
GIST that was successfully resected after imatinib treat-
ment. Although the effects of neoadjuvant imatinib ther-
apy on overall survival are not yet clear, long-term
imatinib administration has the potential to promote
curative surgery for some patients with large GISTs.
Conclusions
We treated a case of a large esophageal GIST that was
successfully resected after neoadjuvant imatinib treat-
ment. When an esophageal GIST is a certain size, lo-
cated in the narrow mediastinal space and is difficult to
dissect, neoadjuvant imatinib treatment might be one of
the options for a minimally invasive surgical resection
without rupture.
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